Abstract:A light-sensitive, externally powered microchip was surgically implanted subretinally near the macular region of volunteers blind from hereditary retinal dystrophy. The implant contains an array of 1500 active microphotodiodes (‘chip’), each with its own amplifier and local stimulation electrode. At the implant's tip, another array of 16 wire-connected electrodes allows light-independent direct stimulation and testing of the neuron–electrode interface. Visual scenes are projected naturally through the eye's le… Show more
“…Patients who are legally blind are the key target population of these therapies. Three different strategies are being investigated: (1) the implantation of differentiated or undifferentiated photoreceptors, 19 (2) electronic retinal implants, [20][21][22] and (3) the subject of this review, so-called 'optogenetic' approaches, [23][24][25] which use genetically encoded light sensors to make cells light responsive. [26][27][28] The success of cellimplantation approaches depends on the formation of functional synapses between the implanted photoreceptors and endogenous bipolar cells, and on functional retinal pigment epithelium to supply photoreceptors with 11-cis-retinal.…”
Section: Potential Therapies For Retinitis Pigmentosamentioning
confidence: 99%
“…Some blind patients can read letters and even words. 22 In optogenetic approaches, a genetically encoded light sensor sits in the membrane of a retinal cell. The generated current flows across the cell membrane and thus activates or inactivates that particular cell.…”
Section: Potential Therapies For Retinitis Pigmentosamentioning
Retinitis pigmentosa (RP) refers to a diverse group of progressive, hereditary diseases of the retina that lead to incurable blindness and affect two million people worldwide. Artificial photoreceptors constructed by gene delivery of light-activated channels or pumps ('optogenetic tools') to surviving cell types in the remaining retinal circuit has been shown to restore photosensitivity in animal models of RP at the level of the retina and cortex as well as behaviorally. The translational potential of this optogenetic approach has been evaluated using in vitro studies involving post-mortem human retinas. Here, we review recent developments in this expanding field and discuss the potential and limitations of optogenetic engineering for the treatment of RP.
“…Patients who are legally blind are the key target population of these therapies. Three different strategies are being investigated: (1) the implantation of differentiated or undifferentiated photoreceptors, 19 (2) electronic retinal implants, [20][21][22] and (3) the subject of this review, so-called 'optogenetic' approaches, [23][24][25] which use genetically encoded light sensors to make cells light responsive. [26][27][28] The success of cellimplantation approaches depends on the formation of functional synapses between the implanted photoreceptors and endogenous bipolar cells, and on functional retinal pigment epithelium to supply photoreceptors with 11-cis-retinal.…”
Section: Potential Therapies For Retinitis Pigmentosamentioning
confidence: 99%
“…Some blind patients can read letters and even words. 22 In optogenetic approaches, a genetically encoded light sensor sits in the membrane of a retinal cell. The generated current flows across the cell membrane and thus activates or inactivates that particular cell.…”
Section: Potential Therapies For Retinitis Pigmentosamentioning
Retinitis pigmentosa (RP) refers to a diverse group of progressive, hereditary diseases of the retina that lead to incurable blindness and affect two million people worldwide. Artificial photoreceptors constructed by gene delivery of light-activated channels or pumps ('optogenetic tools') to surviving cell types in the remaining retinal circuit has been shown to restore photosensitivity in animal models of RP at the level of the retina and cortex as well as behaviorally. The translational potential of this optogenetic approach has been evaluated using in vitro studies involving post-mortem human retinas. Here, we review recent developments in this expanding field and discuss the potential and limitations of optogenetic engineering for the treatment of RP.
“…1C) which replaces the vitreous body in retinal implant patients after vitrectomy [4]. The distant return electrode used in the retinal implant [5] was simulated by setting the outer boundary conditions of the retinal layer to ground potential (Fig. 1D) [6].…”
“…In contrast to traditional gene therapy approaches whose goal is to correct a mutated gene and restore normal protein function, optogenetics introduces novel light sensitive proteins into neurons like bipolar cells and ganglion cells to cause them to function as photoreceptors to restore some visual function (Garg and Federman 2013;Packer et al 2013;Yonehara et al 2013). Retinal prostheses typically consist of arrays of photodiodes that are surgically implanted beneath or above the retina to electrically stimulate the remaining inner retinal cells (Loudin et al 2007;Zrenner et al 2011). Another strategy that is being pursued for patients with very advanced disease is a three-dimensional transplants consisting of stem-cell-derived sheets of photoreceptors and RPE cells grown on a biocompatible polymer scaffold (Zhang et al 2007;Yao et al 2011;Tucker et al 2011a;Shepherd et al 2013).…”
Section: Stem Cells and Genetics Of Retinal Degenerationsmentioning
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.